WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...
For the first time in decades, a new regimen — consolidation Imfinzi after chemoradiation — improved outcomes in patients with limited-stage small cell lung cancer. Imfinzi (durvalumab) when given as ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca's IMFINZI ® (durvalumab) in combination with ...
Nov 14 (Reuters) - Drugmaker AstraZeneca AZN.L said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat unresectable ...
(Reuters) -AstraZeneca said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung cancer, making it the first such ...
Imfinzi perioperative regimen reduced disease progression or death risk by 42% in pCR patients and 23% in those without pCR in MIBC. The regimen lowered the risk of distant metastases or death by 33% ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) has been accepted and granted Priority Review in the US for the treatment ...
AstraZeneca has offered the first look at the benefit of a PD-1/L1 inhibitor when used both before and after surgery in resectable non-small cell lung cancer. But the data raise more questions than ...
The FDA approved Imfinzi with FLOT chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma, based on the MATTERHORN trial results. The MATTERHORN trial demonstrated improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback